Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 3/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.32 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550637 | 0.88 | GCK (0.34) | GCKGRM4PTGDR2FGFR4HAO1 | |
| SCHEMBL3551372 | 0.84 | MET (0.32) | GCKGRM5PTGDR2HAO1MET | |
| SCHEMBL3543751 | 0.74 | GCK (0.44) | GCK | |
| SCHEMBL3549300 | 0.71 | GCK (0.40) | GCK | |
| SCHEMBL3543463 | 0.71 | SLC22A12 (0.35) | GCK | |
| SCHEMBL3545385 | 0.71 | GCK (0.35) | GCKGRM5PTGDR2HAO1 | |
| SCHEMBL3543057 | 0.70 | GCK (0.43) | GCK | |
| SCHEMBL3541036 | 0.70 | DHODH (0.34) | GCK | |
| SCHEMBL3547701 | 0.70 | GCK (0.31) | GCK | |
| SCHEMBL3542510 | 0.69 | CDK8 (0.32) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935890-B1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD KK (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-7799820-B2 | 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20090118304-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1935890-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118304-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | GCKR, GPR119, GCK | GCK 3/4885GRM4 1253/4885GRM5 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.